Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00738751 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract Cancers
A Phase 1 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
NCT00738751 is a Phase 1 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 44 participants.
The verdict
NCT00738751, a Phase 1 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
Study Summary
The main purpose of the study is to: * Determine the safety and tolerability of erlotinib and LBH589B. * Establish a recommended phase II expansion dosing of LBH589B and erlotinib in patients with advanced aerodigestive tract cancers.
Interventions
- DRUG erlotinib
- DRUG Panobinostat (LBH589)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2008-11 |
| Est. Completion | 2015-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00738751
The ClinicalTrials.gov registry entry for NCT00738751 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which erlotinib is the first listed.
NCT00738751 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00738751 about?
NCT00738751 is a clinical study titled "Phase I Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract Cancers". The main purpose of the study is to: * Determine the safety and tolerability of erlotinib and LBH589B. * Establish a recommended phase II expansion dosing of LBH589B and erlotinib in patients with advanced aerodigestive tract cancers.
What is the current status of trial NCT00738751?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2008-11. Estimated completion is 2015-02.
What interventions are being tested in trial NCT00738751?
The interventions under investigation include: erlotinib (DRUG), Panobinostat (LBH589) (DRUG).
Who is sponsoring clinical trial NCT00738751?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.